For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230717:nRSQ1049Ga&default-theme=true
RNS Number : 1049G Porvair PLC 17 July 2023
FOR IMMEDIATE
RELEASE
17 July 2023
Porvair plc
("Porvair" or the "Group" or the "Company")
Acquisition completion
Porvair plc ("Porvair" or the "Group"), the specialist filtration, laboratory
and environmental technology group, announces that on 14 July 2023 it
completed its acquisition of 100% of the issued share capital of two
businesses, Ratiolab GmbH and Ratiolab Kft. (together "Ratiolab"), following
receipt of Hungarian regulatory approval.
As previously announced, Ratiolab GmbH, located outside Frankfurt, sells a
wide range of laboratory consumables in Europe and the Middle East. Ratiolab
Kft., located close to Budapest, manufactures laboratory consumables in an
8,000m(2) facility, the freehold of which is included in the acquisition.
Ratiolab has annual external revenues of around €12 million. The transaction
is expected to be earnings neutral (after acquisition costs) in 2023, and
earnings enhancing thereafter.
The Board believes Ratiolab will fit well into the Group's Laboratory
division, offering a complementary product range and adding European
manufacturing capabilities, injection moulding expertise, and routes to
market.
For further information, please contact:
Porvair plc 01553 765 500
Ben Stocks, Group Chief Executive
James Mills, Group Finance Director
Buchanan Communications 0207 466 5000
Charles Ryland / Simon Compton / Jack Devoy
Notes to Editors
Porvair is a group of specialist filtration, laboratory and environmental
technology businesses. Its businesses design and manufacture a range of
bespoke consumable filtration products that are used in a range of niche
filtration markets. It operates in three divisions: Aerospace &
Industrial; Laboratory; and Metal Melt Quality.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ACQSFWFFLEDSELW